WHO ICTRP trial
A Single-arm, Open-label, Single-center Clinical Study: Safety, Tolerability and…
ChiCTR2200061284 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2200061284 |
|---|---|
| Public title | A Single-arm, Open-label, Single-center Clinical Study: Safety, Tolerability and Preliminary Efficacy of Autologous Anti-CLL1/CLL1+CD33 CAR-T in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children |
| Scientific title | A Single-arm, Open-label, Single-center Clinical Study: Safety, Tolerability and Preliminary Efficacy of Autologous Anti-CLL1/CLL1+CD33 CAR-T in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children |
| Primary sponsor | Sun Yat-sen Memorial Hospital, Sun Yat-sen University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Acute myeloid leukemia |
| Interventions | Group 1 :CAR-T |
| Registration date | Jun 19, 2022 |
| Target size | Group 1 :18 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: